Trametinib, a MEK inhibitor, has demonstrated activity in tumors with NF1 alteration in preclinical models, and clinical activity in low-grade glioma and plexiform neurofibromas in neurofibromatosis type 1. The gene discussed is NF1; the disease is glioma.